NYSE:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $2.78 -0.14 (-4.79%) Closing price 04:00 PM EasternExtended Trading$2.76 -0.01 (-0.54%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About AIM ImmunoTech Stock (NYSE:AIM) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AIM ImmunoTech alerts:Sign Up Key Stats Today's Range$2.70▼$2.9650-Day Range$2.83▼$10.4252-Week Range$2.51▼$39.95Volume148,235 shsAverage Volume65,475 shsMarket Capitalization$2.12 millionP/E RatioN/ADividend YieldN/APrice Target$275.00Consensus RatingBuy Company Overview AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida. Read More AIM ImmunoTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks31st Percentile Overall ScoreAIM MarketRank™: AIM ImmunoTech scored higher than 31% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAIM ImmunoTech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAIM ImmunoTech has received no research coverage in the past 90 days.Read more about AIM ImmunoTech's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for AIM ImmunoTech are expected to decrease in the coming year, from ($0.30) to ($0.35) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of AIM ImmunoTech is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of AIM ImmunoTech is -5.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAIM ImmunoTech has a P/B Ratio of 13.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AIM. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAIM ImmunoTech does not currently pay a dividend.Dividend GrowthAIM ImmunoTech does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for AIM. News and Social Media2.8 / 5News Sentiment0.01 News SentimentAIM ImmunoTech has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for AIM ImmunoTech this week, compared to 2 articles on an average week.Search Interest11 people have searched for AIM on MarketBeat in the last 30 days. This is an increase of 267% compared to the previous 30 days.MarketBeat Follows5 people have added AIM ImmunoTech to their MarketBeat watchlist in the last 30 days. This is an increase of 150% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AIM ImmunoTech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of AIM ImmunoTech is held by insiders.Percentage Held by InstitutionsOnly 12.02% of the stock of AIM ImmunoTech is held by institutions.Read more about AIM ImmunoTech's insider trading history. Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address AIM Stock News HeadlinesAIM ImmunoTech's Oncology Drug Ampligen to Be Featured in Key Presentations and Abstract at the International 5th Annual Marie Skłodowska-Curie Symposium on Cancer Research and Care (MSCI MSCS-2025)August 6 at 9:00 AM | globenewswire.comAIM ImmunoTech Builds Positive Momentum and Reiterates Focus on Driving Ampligen® Clinical Development Toward Pancreatic Cancer ApprovalAugust 4 at 9:00 AM | globenewswire.comProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.August 6 at 2:00 AM | Weiss Ratings (Ad)AIM ImmunoTech Closes $8 Million Public OfferingAugust 1, 2025 | msn.comAIM ImmunoTech Announces Closing of $8.0 Million Public OfferingJuly 31, 2025 | finance.yahoo.comAIM ImmunoTech Inc.: AIM ImmunoTech Announces Pricing of $8.0 Million Public OfferingJuly 30, 2025 | finanznachrichten.deAIM ImmunoTech Shares Drop After $8 Million Offering PricedJuly 30, 2025 | marketwatch.comAIM ImmunoTech reports Ampligen combo trial data for pancreatic cancerJuly 30, 2025 | msn.comSee More Headlines AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $19.80 at the beginning of 2025. Since then, AIM shares have decreased by 86.0% and is now trading at $2.78. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) released its earnings results on Wednesday, November, 15th. The company reported ($16.00) earnings per share (EPS) for the quarter, missing the consensus estimate of ($11.00) by $5.00. The firm earned $0.05 million during the quarter. AIM ImmunoTech had a negative net margin of 12,594.21% and a negative trailing twelve-month return on equity of 421.73%. When did AIM ImmunoTech's stock split? AIM ImmunoTech shares reverse split before market open on Thursday, June 12th 2025.The 1-100 reverse split was announced on Wednesday, June 11th 2025. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, June 11th 2025. An investor that had 100 shares of stock prior to the reverse split would have 1 shares after the split. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), iBio (IBIO), Vaxart (VXRT), Meta Platforms (META), Sorrento Therapeutics (SRNE), NIO (NIO) and T2 Biosystems (TTOO). Company Calendar Last Earnings11/15/2023Today8/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNYSE:AIM CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees20Year Founded1990Price Target and Rating Average Price Target for AIM ImmunoTech$275.00 High Price Target$450.00 Low Price Target$100.00 Potential Upside/Downside+9,792.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($24.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$28.96 million Net Margins-12,594.21% Pretax Margin-12,594.21% Return on Equity-421.73% Return on Assets-147.54% Debt Debt-to-Equity Ratio0.05 Current Ratio0.75 Quick Ratio0.75 Sales & Book Value Annual Sales$146 thousand Price / Sales14.55 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book13.90Miscellaneous Outstanding Shares764,000Free Float68,740,000Market Cap$2.12 million OptionableNot Optionable Beta0.89 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NYSE:AIM) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredInstant Cash (every 3rd Monday)Since 1973, Wall Street has quietly used a strange little pricing quirk to cash flow billions. Now, for the...Awesomely, LLC | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredAltucher: $900 to $108,000? Trump’s “Great Gain” Is HereJames Altucher says two recent events could trigger a historic wealth shift—one driven by a radical Trump poli...Paradigm Press | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.